Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease

Calliditas Therapeutics CALT has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy (IgAN).

  • IgAN, also known as Berger's disease, is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) builds up in the kidneys, resulting in hampering the kidneys' ability to filter waste from the blood.
  • The company has applied for accelerated approval, which allows drugs targeting serious conditions to be approved based on a surrogate endpoint.
  • The surrogate endpoint in the Phase 3 trial, NefIgArd, was reducing proteinuria versus placebo and demonstrated a statistically significant reduction in the urine protein.
  • A confirmatory study designed to provide data on a long-term renal benefit is fully recruited and is expected to read out in early 2023.
  • The company says if approved, Nefecon would become the first therapy specifically designed and approved for the treatment of IgAN, with the potential to be disease-modifying.
  • Price Action: CALT shares gained 3.6% at $31.03 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBerger's diseaseKidney Diseases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!